Spermatocytic tumor of the testis: A case report and mini­review of the literature.

Spermatocytic tumors are a rare type of testicular cancer, comprising <1% of all testicular malignancies. This type of cancer typically affects males in their 60s and 70s and rarely metastasizes; however, it poses a threat to the health of affected individuals if left untreated. The present study describes the case of a 68-year-old male patient with this type of tumor, including a presentation of his initial symptoms, treatment and subsequent monitoring. A male patient, aged 68 years, visited the authors' clinic with an asymptomatic mass in the right testicle. The mass had been progressively increasing in size for a duration of 5 years following a history of blunt injury. During the examination, a noticeable, painless enlargement was detected in the right testis, whereas the left testis appeared to be in a normal state. Tumor markers were within normal limits. Imaging revealed a complex mass (11x8x7 cm) almost replacing the right testis, with no detectable lymph nodes. A right radical orchidectomy was performed under spinal anesthesia. A histopathological examination revealed a spermatocytic tumor. The post-operative period was uneventful, with no metastasis detected in the CT scans. The patient was discharged with instructions for regular follow-up appointments. The case presented herein highlights a rare spermatocytic tumor in a 68-year-old male. The early detection and treatment of testicular tumors, regardless of age, are crucial for a good prognosis.

An unusual case of spermatocytic seminoma in 80 year-old-patient: A case report.

INTRODUCTION: and importance: Testicular tumors represent 1% of human malignant tumors. Spermatocytic seminoma (SS) is a rare tumor, representing less than 2% of testicular cancers. This Tumor is an uncommon neoplasm first described by Masson in 1946 and rarely occurs before the fifth decade. Around 200 cases of Spermatocytic seminoma have been reported in the literature. CASE PRESENTATION: We present a case of Spermatocytic seminoma in 80 years old men who presented with a right testis mass. Scrotal ultrasonography revealed a well-defined 62 × 32 × 27 mm right testicular solid tumor with heterogeneous echogenicity associated with a small hydrocele. A right inguinal orchiectomy was performed with primary control of the spermatic cord. Following the operation, the patient was followed closely without any adjuvant therapy and was in good condition with no evidence of metastasis 12 months after the operation. CLINICAL DISCUSSION: The spermatocyte seminoma described by Masson in 1946, represents an entity anatomy-clinical which, due to its morphological and biological properties particular, deserves to be distinguished from the classic variety of testicular seminomas. It is an uncommon tumor and, represents less than 1% of all patients and 4.4% of stage I. Homolateral orchiectomy inguinal with upper spermatic cord ligature represented the standard treatment. CONCLUSION: Spermatocytic seminoma is a rare tumor, found mainly in elderly men. It is original by its histological characteristics and its good prognosis.

The contributions of Juan Rosai to testicular pathology with personal remembrances.

The authors summarize their personal interactions with someone for whom they had unbounded admiration, Dr. Juan Rosai. This varied from daily review of cases, to sharing the platform at meetings, being under his tutelage as an author, and co-directing postgraduate courses. These all highlighted the remarkable knowledge of medicine Dr. Rosai had, imparting as he did diagnostic pearls and remarks on the literature including the history of our discipline, often laced with a well-honed sense of humor. The contributions he made to the pathology of the testis are then considered beginning with his role in highlighting a tumor, at the time not particularly well publicized, spermatocytic seminoma. He wrote two major papers on it, one on standard clinical and pathologic aspects, and one on its ultrastructure. The first was associated with his diligent investigation of a prior paper reporting an unusually high number of malignant examples of this tumor but on review that was explained by their representing malignant lymphoma. The organizational skills of Dr. Rosai, and attention to detail, were second to none and shown perhaps most notably with his organizing many courses, but they were also illustrated early in his career when he moderated a symposium on germ cell tumors of the testis which laid the framework for the classification and nomenclature of premalignant lesions. Finally, his almost career-long interest in the entity he codiscovered, Rosai-Dorfman disease, was associated with his reporting testicular involvement by that disorder in his later years. This giant figure in pathology will stand forever in the top tier with other greats who have contributed to the field.

Spermatocytic seminoma of testis associated with undifferentiated sarcoma revealed in metastatic disease: A review and case report analysis.

Spermatocytic seminoma is a relatively rare testicular tumor and is characterized by a good prognosis. The discovery of a sarcomatous contingent modifies the prognosis of the indolent neoplasm. Only 20 cases being reported in English literature. We present the case of a 66-year-old man with a two-year history of left-sided scrotal pain and swelling. Tumor markers were normal. Ultrasound demonstrated a very large solid-cystic testicular mass. Orchidectomy was performed. Further imaging investigations revealed lung, vertebra, and retroperitoneal lymph node metastases. Histological examination and immunohistochemistry of the orchidectomy specimen concluded on spermatocytic seminoma associated with undifferentiated sarcoma component.

A systematic review of treatment outcomes in localised and metastatic spermatocytic tumors of the testis.

INTRODUCTION: Because spermatocytic tumors of the testis are rare, only limited evidence exists regarding the malignant potential and the optimal management of localized and metastatic disease. MATERIALS AND METHODS: We performed a systematic review through MEDLINE, EMBASE, Scopus, Cochrane Database of Systematic Reviews and Web of Science to identify reports including patients with testicular spermatocytic tumors. RESULTS: From originally 7863 studies, we extracted data of 146 patients of which 99% were treated with radical orchiectomy. Metastases in patients with initially localised disease were diagnosed in 7% of patients and detected after a median follow-up of 5.5 months (range 2-21 months). Patients with aggressive histology (sarcoma or anaplastic subtype) were more likely to have metastatic disease (6/124 (5%) vs 9/22 (41%), p < 0.001). Patients with metastatic disease had larger primary tumors (92.5 vs 67.5 mm, p = 0.05). Life expectancy in patients with metastatic disease ranged from 1 to 25 months. CONCLUSION: The published literature does neither support the use of testis sparing surgery nor adjuvant therapy. Patients with aggressive variants or larger tumors were more likely to have metastases and develop recurrences within the first few years. Patients with metastatic disease have a limited life expectancy and metastatic spermatocytic tumors are not as responsive to chemotherapy as germ cell cancers.

Spermatocytic seminoma with rhabdomyoblastic differentiation: Case report and review of literature.

Spermatocytic seminoma (SCS) is an indolent germ cell tumor of the testis. It has an excellent prognosis and orchidectomy is generally curative. Very rarely, it can be complicated by a sarcomatous transformation which is associated with a very aggressive behavior and requires adjuvant therapy. SCS with sarcomatous component is a very rare occurrence with <20 cases described in the world literature of which eight showed rhabdomyoblastic differentiation. We report a case of SCS with rhabdomyosarcomatous differentiation in a 60-year-old male along with a short review of literature.

Proceedings of the 2017 National Toxicology Program Satellite Symposium.

The 2017 annual National Toxicology Program Satellite Symposium, entitled "Pathology Potpourri," was held in Montreal, Quebec, Canada at the Society of Toxicologic Pathology's 36th annual meeting. The goal of this symposium was to present and discuss challenging diagnostic pathology and/or nomenclature issues. This article presents summaries of the speakers' talks along with select images that were used by the audience for voting and discussion. Various lesions and other topics covered during the symposium included renal papillary degeneration in perinatally exposed animals, an atriocaval mesothelioma, an unusual presentation of an alveolar-bronchiolar carcinoma, a paraganglioma of the organ of Zuckerkandl (also called an extra-adrenal pheochromocytoma), the use of human muscle samples to illustrate the challenges of manual scoring of fluorescent staining, intertubular spermatocytic seminomas, medical device pathology assessment and discussion of the approval process, collagen-induced arthritis, incisor denticles, ameloblast degeneration and poorly mineralized enamel matrix, connective tissue paragangliomas, microcystin-LR toxicity, perivascular mast cells in the forebrain thalamus unrelated to treatment, and 2 cases that provided a review of the International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) bone nomenclature and recommended application of the terminology in routine nonclinical toxicity studies.

Spermatocytic Tumor With Sarcoma: A Rare Testicular Neoplasm.

Spermatocytic tumor, formerly known as spermatocytic seminoma, is an uncommon testicular neoplasm which is a distinct clinicopathologic entity from classic seminoma. These tumors are not associated with germ cell neoplasia in situ, other germ cell tumors, or isochromosome 12p. Although typically, these tumors have an excellent prognosis occasional cases are associated with sarcoma and have a very poor prognosis. We present a case of spermatocytic tumor with sarcoma showing a chondrosarcomatous component, discuss the pathologic findings and differential diagnosis and provide follow-up information.

Intratubular spermatocytic seminomas in 2 sprague-dawley rats.

This report describes 2 cases of spontaneous intratubular spermatocytic seminomas in Sprague-Dawley rats. These rats were sacrificed at 10 weeks old (case 1) and 40 weeks old (case 2), respectively. Macroscopically, there were no remarkable changes in either case. Microscopically, tumor cells were observed within a single seminiferous tubule (case 1) or several seminiferous tubules (case 2). The proliferating tumor cells were a tripartite cell population comprising small lymphocyte-like, intermediate-sized or large-sized cells, with frequent mitoses, arranged in sheets or forming a basal layer around a tubule or tubules. Immunohistochemically, the tumor cells were strongly positive for proliferating cell nuclear antigen and weakly positive for c-kit, neuron specific enolase and VASA. Our cases provide valuable background control information for the occurrence of seminoma in rats.

Reaction to Koppad SN et al. Bilateral spermatocytic seminoma: an update on "synchronous" and "sequential" presentation of this rare variant of testicular tumour.

We read with interest the report of Koppad and colleagues in the Pan African Medical Journal describing a case of bilateral synchronous presentation of spermatocytic seminoma in an elderly Indian male. While we appreciate their efforts in documenting this rare presentation, we disagree with the reported figures as outlined in the report and wish to draw attention of the authors as well as the readers of the journal to the gross inaccuracies in the reported statistics. We present our data, following a comprehensive literature review, to unveil the magnitude of bilateral presentation (synchronous and sequential) of this unique variant of testicular tumor as reported in medical literature to facilitate dissemination of precise information on the topic.

Bilateral synchronous spermatocytic seminoma: a rare case report.

Testicular tumors are very common among man under the age of 45 years. The case of bilateral synchronous testicular seminoma is very rare. We present a case of bilateral synchronous testicular seminoma stage-I in a 42-year old Indian male who came to our hospital with chief complaints of dull ache in the abdomen and groin, bilateral scrotal swelling and heaviness, left-sided scrotal swelling since last four years, and right-sided since last two years. He underwent bilateral orchidectomy followed by radiotherapy. In this case we throw light on this rare condition and discuss the management.

Spermatocytic variant of classic seminoma: a report of five cases and a brief review of the literature.

BACKGROUND: Spermatocytic seminoma is a rare testicular malignancy, appearing in the adult population. It has a good prognosis and a low rate of metastatic potential. OBJECTIVES: We present five cases diagnosed and treated with radiotherapy at Rambam Health Care Campus in Haifa, Israel. METHODS: Between 1974 and 1996, five patients with stage I spermatocytic seminoma were referred post-orchiectomy to the Northern Israel Oncology Center. All five patients presented with the typical pathological features of the spermatocytic variant of classic seminoma, and all were staged clinically and radiologically. RESULTS: Mean age at diagnosis was 44 years (range 30-58 years). Main symptoms included a palpable testicular mass and/or testicular enlargement. Mean duration of symptoms was 9 months (range 0.5-24 months). Three patients were irradiated to the para-aortic/ipsilateral iliacal lymph nodes (mean total dose 2,500 cGy), one patient with 4,000 cGy. One patient was irradiated to the bilateral iliacal lymph nodes (2,600 cGy). With a median follow-up of 15 years, four patients are alive with no evidence of disease or severe late side effects. One patient developed severe lymphedema and symptomatic peripheral vascular disease, stage IIA prostate carcinoma (hormonal and brachytherapy treatment) and a non-secretory hypophyseal adenoma (surgically removed); he died at the age of 75 due to severe peripheral vascular and coronary heart disease with no evidence of his first or second primaries. CONCLUSIONS: Prognosis is excellent and does not differ from classic seminoma. As in the accumulated experience in early-stage, low-risk classic seminoma, we suggest surveillance as the preferred policy.

Bilateral spermatocytic seminoma: a case report.

Spermatocytic seminoma (SS) is a rare entity, accounting for 2%-12% of all seminomas; amongst those, fewer than 10% are bilateral. These may occur synchronously or metachranously. We report here a case of bilateral SS in a 63-year-old patient, who initially presented with bilateral testicular masses. In our search of the literature, this represents the fifth documented case of synchronous, bilateral SS.

The utility of immunostaining for NUT, GAGE7 and NY-ESO-1 in the diagnosis of spermatocytic seminoma.

AIMS: To identify specific positive immunohistochemical markers for spermatocytic seminoma (SS). METHODS AND RESULTS: We studied the reactivity of 94 (total) cases of SS, seminoma, embryonal carcinoma and solid yolk sac tumour with antibodies against nuclear protein in testis (NUT) and two cancer/testis antigens, GAGE7 and NY-ESO-1. When tumour positivity was defined as an extent plus intensity score of ≥ 4, NUT was positive in 71% of SSs, 19% of seminomas, and 5% of solid yolk sac tumours. GAGE7 was positive in 67% of SSs and 4% of seminomas. NY-ESO-1 was positive in 82% of SSs, 13% of seminomas, and 5% of solid yolk sac tumours. The sensitivity and specificity, respectively, of these antibodies for SSs were as follows: NUT, 71% and 92%; GAGE7, 67% and 99%; and NY-ESO-1, 82% and 94%. When positivity criteria were stricter, NUT and GAGE7 positivity occurred exclusively in SS, but the sensitivity decreased to 41% and 60%, respectively, and NY-ESO-1 was 59% sensitive and 97% specific. Neither the sarcomatous component of three SSs nor any embryonal carcinoma showed reactivity with any antibody. CONCLUSIONS: All three antibodies are variably sensitive for SS, and high specificity is attained when there is multifocal and strong nuclear labelling.

The management of retroperitoneal lymphadenopathy in spermatocytic seminoma of the testicle.

Spermatocytic seminoma is an extremely rare clinically and pathologically distinct subtype of testicular cancer that infrequently metastasizes and typically yields a good prognosis. While retroperitoneal lymphadenopathy in the typical testicular cancer patient often harbors metastatic disease, in a patient with spermatocytic seminoma this finding should be viewed with suspicion, and pathologic confirmation of metastatic disease is essential. We present a 49-year-old man with spermatocytic seminoma and retroperitoneal and mesenteric lymphadenopathy who was found to have concurrent low-grade lymphoma.

Spermatocytic seminoma: a 21 years' retrospective study in a tertiary care hospital in Pakistan.

BACKGROUND: Spermatocytic seminoma is a rare testicular germ cell tumor of old men. Accounting for 1-4% of all seminomas, spermatocytic seminomas have distinct pathogenesis, histological features, immunohistochemical profile and comparatively benign clinical behavior which distinguishes them from other germ cell tumors, especially classic seminoma. AIMS: The purposes of our study were to assess the patient demographics, pathological features and to evaluate the utility of CD 117 immunostain along with other immunohistochemical stains in distinguishing Spermatocytic seminomas from classic seminomas. MATERIAL AND METHODS: All spermatocytic seminomas patients diagnosed during 1992 to 2013 at Section of Histopathology, Department of Pathology and Microbiology, Aga Khan University hospital were included. Patient characteristics, histological details and follow-up data of few patients were available. CD 117 expression was determined by immunohistochemistry. RESULTS: Total 16 cases of Spermatocytic seminomas were reviewed. Median age was 60 years and average tumor size was 10.4 cms. Microscopically, all of the 16 cases showed presence of edema and absence of lymphocytic infiltrate and intratubular germ cell neoplasia. Cytoplasmic glycogen was negative in all 13 cases, PLAP immunostain was negative in all 12 cases, while CD 117 was positive in all 8 cases, where applied. CONCLUSION: CD 117 is of limited utility in differentiating the spermatocytic seminoma from classic seminoma as it is expressed in significant number of spermatocytic seminomas. However, different histological features, PAS special stain and PLAP immunostain are significantly helpful in distinguishing these two entities.

Rhabdomyosarcomatous differentiation in a spermatocytic seminoma with review of literature.

The sarcomatous differentiation occurring in spermatocytic seminoma (SS) renders an aggressive behavior with metastatic potential to this relatively indolent neoplasm. Correct identification of this sarcomatous component is essential as further management differs. Herein, we report a case of young male with SS with rapid increase in size of the tumor. Histopathology revealed a rhabdomyosarcomatous component infiltrating the rete-testis and epididymis along with a well-circumscribed SS.